serine has been researched along with Parkinson Disease, Secondary in 8 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, YD | 1 |
| Bao, XQ | 1 |
| Xu, S | 1 |
| Yu, WW | 1 |
| Cao, SN | 1 |
| Hu, JP | 1 |
| Li, Y | 1 |
| Wang, XL | 1 |
| Zhang, D | 1 |
| Yu, SS | 1 |
| Lu, M | 1 |
| Fan, Y | 1 |
| Tang, M | 1 |
| Qian, X | 1 |
| Ding, J | 1 |
| Hu, G | 1 |
| Wessell, RH | 1 |
| Ahmed, SM | 1 |
| Menniti, FS | 1 |
| Dunbar, GL | 1 |
| Chase, TN | 2 |
| Oh, JD | 2 |
| Vaughan, CL | 1 |
| Gründig, E | 1 |
| Raheem, KA | 1 |
| Salvenmoser, F | 1 |
| Schedl, R | 1 |
| Weiss, J | 1 |
| Teelken, AW | 1 |
| van den Berg, GA | 1 |
| Muskiet, FA | 1 |
| Staal-Schreinemachers, AL | 1 |
| Wolthers, BG | 1 |
| Lakke, JP | 1 |
| Narabayashi, H | 2 |
| Kondo, T | 1 |
| Yokochi, F | 1 |
| Nagatsu, T | 1 |
8 other studies available for serine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2016 |
Potentiation of D-serine involves degeneration of dopaminergic neurons in MPTP/p mouse model of Parkinson's disease.
Topics: Animals; Astrocytes; DNA-Binding Proteins; Dopamine; Drug Synergism; Fluorescent Antibody Technique; | 2011 |
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Topics: Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Locomotion; Male; Neost | 2004 |
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antibodies; Antiparkinson Agent | 1999 |
Drug-induced parkinsonism in the rat- a model for biochemical investigation of the parkinson-syndrome. III. The incorporation of D-glucose-14C(U) in amino acids of brain and liver from rats pretreated with reserpine or with phenothiazines.
Topics: Amino Acids; Animals; Antipsychotic Agents; Brain; Glucose; Glutamates; Glutamine; Glycine; Liver; M | 1976 |
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Dopamine; Droxidopa; Female; Homovanillic Acid | 1989 |
[L-threo-DOPS therapy and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Huma | 1986 |
Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
Topics: Adult; Aged; Antiparkinson Agents; Droxidopa; Drug Evaluation; Drug Therapy, Combination; Female; Hu | 1987 |